Lung Adenocarcinoma — Trials

Lung Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

231 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 52
Recruiting: 27
Ph III recruiting: 6
Growth YoY: —
Industry share: 13%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (28)

clinicaltrialsPublishedShowing 1–12 of 12 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04105270	RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial	recruiting	Phase 2	82	Masonic Cancer Center, University of MinnesotaOTHER	1	Sep 17, 2026	clinicaltrials
NCT07341737	SL-28 for Advanced Solid Tumours	recruiting	Phase 1 / Phase 2	60	Second Life TherapeuticsINDUSTRY	1	Sep 15, 2026	clinicaltrials